Telangana Life Sciences Ecosystem Reaches $145 Bn Valuation as INR 84,000 Cr Investments Accelerate Growth
Advertisement
Officials said several memorandum-backed projects linked to Green Pharma City are currently in different stages of implementation, with proposals estimated at around INR 20,000 Cr.
Telangana's life sciences ecosystem has reached an estimated $145 billion valuation, driven by over INR 84,000 Cr in investments in the last two years, strengthening Hyderabad’s standing as a global hub for pharmaceuticals, biotech, medtech, and health innovation.
The latest milestone was reviewed during the seventh board meeting of the Telangana Life Sciences Foundation (TLSF), chaired by Industries and Commerce Minister D. Sridhar Babu.
State officials noted that the ecosystem has expanded nearly threefold since 2016, with the most rapid phase of growth taking place recently through new investments, industrial projects, and global collaborations.
D. Sridhar Babu said Telangana is preparing for its next phase of ecosystem-led growth through a new life sciences policy aimed at strengthening innovation, research capabilities, and global competitiveness.
Hyderabad Strengthens Position as a Global Healthcare Hub
Telangana currently contributes close to 40% of India’s pharmaceutical production and nearly one-third of global vaccine output, reinforcing Hyderabad’s long-standing identity as the “Vaccine Capital of the World.”
The city has also evolved into a major destination for research, development, and advanced manufacturing across pharmaceuticals, biotechnology, medical devices, genomics, and health technology.
A key factor behind the sector’s rise has been the growing presence of multinational companies.
According to TLSF, Hyderabad now hosts technology and innovation centres of nine of the world’s top ten life sciences companies, making it the only region outside the United States with such a concentration.
Industry observers view this as a strong indicator of the city’s increasing strategic relevance in global healthcare and life sciences operations.
Infrastructure Expansion & Future Growth Plans
The state government has also focused on creating specialised infrastructure to support long-term growth. Projects such as Genome Valley, Medical Devices Park, and the upcoming Green Pharma City have been positioned as major anchors for investment and manufacturing expansion.
Officials said several memorandum-backed projects linked to Green Pharma City are currently in different stages of implementation, with proposals estimated at around INR 20,000 Cr.
The government is also expected to focus on talent development and institutional capacity building, including the proposed Telangana School of Life Sciences.
The meeting also acknowledged the contribution of outgoing TLSF CEO Shakthi M. Nagappan, who played a key role in expanding the ecosystem and attracting investments during his tenure.
Nagappan has now been appointed Advisor (Lifesciences) to the government and will continue as a member of the TLSF board. Newly appointed CEO Sarvesh Singh outlined priorities for 2026-27, including sustaining investment momentum and accelerating execution of strategic projects.
Stay tuned for more such updates on Digital Health News
